New Trustee announcement

TreatSMA are extremely happy and proud to announce that Marni Smyth has become the sixth trustee that has joined our team. Marni has been in discussions with TreatSMA for a number of weeks and we take great pleasure in announcing the news.

Hi Everyone

I’m Marni and I have SMA type 2 and live independently with the help of my Mafia (my nickname for my team of Personal Assistants). Outside of TreatSMA I am a student at the University of Huddersfield researching how to make screen printing (traditional textile printing process) accessible for people living with NMD.

In my spare time I love doing makeup, I have a makeup based Instagram (@marni.smyth) where I post all my looks. This is a hobby that I hope to turn into a career at some point in the future.

I have been following and participating in TreatSMA campaigns and protests now for two plus years. I truly believe in the ethos and drive behind TreatSMA’s work, so when I was asked if I wanted to become a trustee, I was so excited to be a part of the team. I hope to bring insight, added drive and further perspective from a person living with SMA. I also hope to help run some fun online community events to boost the community’s spirits during this scary time.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more